SCHEMBL9937633

SCHEMBL9937633

c1ccc(-c2nc(Nc3ccc4c(c3)OCCO4)c3ccccc3n2)cc1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCG2 Q9UNQ0 14/20 0.74
KDM1A O60341 2/20 0.69
MEN1 O00255 5/20 0.67
KMT2A Q03164 5/20 0.67
TP53 P04637 4/20 0.67
LMNA P02545 3/20 0.67
ALDH1A1 P00352 2/20 0.67
CYP1A2 P05177 2/20 0.67
CYP3A4 P08684 2/20 0.67
CYP2D6 P10635 2/20 0.67
MAPK1 P28482 2/20 0.67
CYP2C19 P33261 2/20 0.67
HSD17B10 Q99714 2/20 0.67
USP2 O75604 1/20 0.67
ALOX15 P16050 1/20 0.67
TSHR P16473 1/20 0.67
CLK4 Q9HAZ1 1/20 0.67
MAPT P10636 3/20 0.61
KDM4E B2RXH2 1/20 0.61
CYP2C9 P11712 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6001170 0.87 LMNA (0.77) ABCG2KDM1AMEN1KMT2ATP53
SCHEMBL22201446 0.86 ALDH1A1 (0.80) ABCG2MEN1KMT2ATP53LMNA
SCHEMBL12316850 0.85 MEN1 (0.73) ABCG2KDM1AMEN1KMT2ATP53
SCHEMBL2293460 0.82 MEN1 (0.69) ABCG2KDM1AMEN1KMT2ATP53
SCHEMBL22201610 0.79 HPGD (0.59) ABCG2MEN1KMT2ATP53LMNA
SCHEMBL2294663 0.78 KDM1A (0.66) ABCG2KDM1AMEN1KMT2ATP53
SCHEMBL18292491 0.78 MAPT (0.64) ABCG2KDM1AMEN1KMT2AALDH1A1
SCHEMBL1063103 0.78 ABCG2 (1.00) ABCG2KDM1AMEN1KMT2ATP53
SCHEMBL6001380 0.77 PDE5A (0.67) ABCG2KDM1AMEN1KMT2ATP53
SCHEMBL4868573 0.77 ABCG2 (1.00) ABCG2KDM1AMEN1KMT2ATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160354375-A1 CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES SUCH AS TAUOPATHIES ELECTROPHORETICS LIMITED (GB) 2016-12-08 US claimed
US-20140031547-A1 CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODE-GENERATIVE DISEASES SUCH AS TAUOPATHIES ELECTROPHORETICS LIMITED 2014-01-30 US claimed
EP-2651405-A2 CASEIN KINASE 1 (CK1 ) INHIBITORS Electrophoretics Limited (GB) 2013-10-23 EP claimed
WO-2012080729-A2 CASEIN KINASE 1δ (CK1δ) INHIBITORS ELECTROPHORETICS LIMITED (GB) 2012-06-21 WO claimed
US-20240000821-A1 CHEMICAL INHIBITORS AGAINST KINASES TO BLOCK TELOMERE ELONGATION IN CANCER UNIV JOHNS HOPKINS (US) 2024-01-04 US disclosed
US-20200078387-A1 CHEMICAL INHIBITORS AGAINST KINASES TO BLOCK TELOMERE ELONGATION IN CANCER THE JOHNS HOPKINS UNIVERSITY 2020-03-12 US disclosed
WO-2018112342-A1 CHEMICAL INHIBITORS AGAINST KINASES TO BLOCK TELOMERE ELONGATION IN CANCER THE JOHNS HOPKINS UNIVERSITY (US) 2018-06-21 WO disclosed
US-20160354375-A1 CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES SUCH AS TAUOPATHIES ELECTROPHORETICS LIMITED (GB) 2016-12-08 US disclosed
US-20160354375-A1 CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES SUCH AS TAUOPATHIES ELECTROPHORETICS LIMITED (GB) 2016-12-08 US disclosed
US-20140031547-A1 CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODE-GENERATIVE DISEASES SUCH AS TAUOPATHIES ELECTROPHORETICS LIMITED 2014-01-30 US disclosed
US-20140031547-A1 CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODE-GENERATIVE DISEASES SUCH AS TAUOPATHIES ELECTROPHORETICS LIMITED 2014-01-30 US disclosed
EP-2651405-A2 CASEIN KINASE 1 (CK1 ) INHIBITORS Electrophoretics Limited (GB) 2013-10-23 EP disclosed
WO-2012080729-A2 CASEIN KINASE 1δ (CK1δ) INHIBITORS ELECTROPHORETICS LIMITED (GB) 2012-06-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140031547-A1 CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODE-GENERATIVE DISEASES SUCH AS TAUOPATHIES CSNK1G1, CSNK1A1, CSNK1G3 ABCG2 4649/4885KDM1A 493/4885MEN1 3661/4885
US-20160354375-A1 CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES SUCH AS TAUOPATHIES CSNK1G1, CSNK1A1, CSNK1D ABCG2 4161/4885KDM1A 563/4885MEN1 3510/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.